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Abstract
Background: Chronic kidney disease (CKD) is associated with an increased risk of fracture and cardiovascular mortality.
The risk of fracture in hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation (KT) is higher when
compared to the general population. However, uncertainties remain about which group has the highest risk of
fracture. We aim to identify the risk of fracture and cardiovascular mortality post-fracture in HD compared to PD
or KT and in PD compared to KT population.
Methods: We will conduct a systematic review of observational studies and randomized control trials on patients
with CKD. Eligible studies will be searched on MEDLINE, Embase, Web of Science, Cochrane Library, and in gray
literature. Two independent reviewers will screen all identified references in order to include studies reporting the
risk of fracture without a comparator or comparing that risk in HD vs KT, PD vs KT, or HD vs PD. Studies comparing the
risk of fracture in a renal replacement therapy group to general population or to non-dialyzed CKD patients will also be
included. Data on study settings, population characteristics, intervention, comparator, and outcomes will be extracted.
Study data will be summarized and analyzed in RevMan and SAS. Risk of bias in cohort design studies will be assessed
with an adapted version of the ROBINS-I tool and by the Cochrane handbook tool for RCTs. The quality of evidence
and strengths of recommendations will be evaluated by the Grading of Recommendations Assessment, Development
and Evaluations (GRADE) tool. We will pool relative risks with random-effect models and Mantel-Haenszel methods.
Subgroup and sensitive analysis are planned according to the intervention and comparator, study design, and type
of fracture.
Discussion: This review will provide new pooled data about fracture risk in dialysis and KT patients. Our results should
guide the implementation of future preventive strategies targeting patients with the highest fracture risk. A pooled
analysis of observational studies could be limited by a probable considerable heterogeneity among these studies.
Systematic review registration: PROSPERO CRD42016037526
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Background
Chronic kidney disease (CKD) is becoming a major public
health issue worldwide. In 2011, more than 615,000 people
suffered from end-stage renal disease (ESRD) in the USA
[1]. In 2013, statistics in Canada estimated that 41,914
Canadians suffered from ESRD [2]. Kidney function
decline leads to metabolic disorders that affect bone me-
tabolism and vascular health known as CKD-mineral and
bone disorder (CKD-MBD) [3]. Clinically, CKD-MBD has
been associated with an increased risk of fracture and car-
diovascular mortality post-fracture [4–8].
Patients with ESRD will eventually require renal re-
placement therapy [9]. Therefore, these patients are
treated by hemodialysis (HD), peritoneal dialysis (PD),
or kidney transplantation (KT). In 2013, the proportion
of patients treated by each modality was 47.37 vs 10.13%
vs 42.51%, respectively, in Canada [2]. The increased risk
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of fracture in HD, PD, and KT patients, compared to the
general population is well documented [4, 10, 11].
Indeed, the risk of hip fracture in ESRD is estimated
to be 4- to 14-fold the risk seen in the general popu-
lation [4, 11]. However, there exists a knowledge gap
on the risk of fracture between these three groups of
patients.
While Beaubrun et al. [12] reported in the USA that
the incidence rate of hip fractures in HD patients was
20.6 per 1000 person-years in 2009, Nair et al. [13], in
the same design study, reported a much lower incidence
rate in KT patients, estimated at 3.8 per 1000 person-
years. In contrast, another study has reported that the
risk of hip fracture was in fact 1.34-fold higher in KT vs
dialysis patients [14]. When comparing patients in dialy-
sis, a recent study [15] has found that the risk of hip
fracture in HD was 1.74-fold higher than that in PD,
while another study did not find any difference between
HD, PD, and KT patients [5]. Given these finding dispar-
ities, a systematic review is required to provide clear in-
formation on the incidence of fracture in dialysis and
kidney transplant population.
Why is it important to do this review?
Uncertainties remain concerning the risk of fracture be-
tween HD, PD, and KT patients. It is clinically important
to obtain these data in order to implement fracture pre-
vention strategies and treatments in this population.
Based on previous available literature, one of the reasons
that could explain the higher risk of fractures in HD pa-
tients might be their increased number of comorbidities
as compared to PD and KT population. On the other
hand, KT patients may also have a higher fracture risk
due to the use of glucocorticoids to reduce the risk of
graft rejection [16, 17]. Clearly, this review will provide
new, robust, and clinically useful data on the incidence
of fracture in HD, PD, and KT patients and whether the
risk of fracture is different.
Objectives
Primary objective
Identify the risk of fracture in HD compared to PD or
KT and in PD compared to KT populations.
Secondary objective
Identify the risk of cardiovascular mortality post-fracture
in HD compared to PD or KT and in PD compared to
KT populations.
Methods
We will conduct a systematic review based on the pre-
ferred reporting items for systematic reviews and meta-
analyses (PRISMA) statement [18] and the Cochrane
handbook for systematic reviews of interventions
methodological recommendations [19]. This protocol is
based on the checklist of the PRISMA-P for systematic
reviews protocol [20] (See Additional file 1).
Eligibility criteria
Study design
We will include in our review randomized control trials
(RCTs) (even if they are not likely to provide us with the
data we seek) and observational studies (cohort studies,
cross sectional studies, case-control studies). Meeting
abstracts will be included in our review only if they pro-
vide all the necessary information. Case report studies
will be excluded.
Type of participants
To be included in our review, studies should have in-
cluded adults ≥18 years (at least 80% of participants) of
CKD treated by either hemodialysis, kidney transplant-
ation, or peritoneal dialysis.
Type of intervention
The intervention of interest is renal replacement therapy
(HD, PD, and KT).
Comparator
To be included in our review, the comparator used
should be either no comparator group, general popula-




The primary outcome will be the risk (incidence rate, in-
cidence proportion, odds, or prevalence) of fracture (hip,
vertebral, and any fracture).
Secondary outcomes
1. Fracture sites (hip, vertebral, non-vertebral).
2. Risk of cardiovascular mortality post-fracture.
3. All-cause mortality associated with fracture.
4. Length of hospitalization post-fracture.
5. Number of hospitalizations post-fracture (during the
following year).
Information sources
We will systematically search MEDLINE, Embase, Web
of science, and The Cochrane Library (from their incep-
tion up to a maximum of 6 months’ prior submission
for publication, in order to include as many trials as pos-
sible) for studies eligible to our review. We will consult
Google Scholar and thesis repositories to identify add-
itional studies, including Thesis Canada Portal, EtHOS,
DART-Europe E-Theses Portal, the National Library of
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Australia’s TROVE, and ProQuest Dissertations & The-
ses Global.
Search strategy
The search strategy is based on keywords related to the
intervention (hemodialysis, peritoneal dialysis, kidney
transplantation, and all synonyms) and related to the
outcome (keywords related to fracture and synonyms). A
strategy has been first established for PubMed and
Embase and adapted to other databases. We will not set
any restrictions for the language or year of publication.
An additional file shows the search strategy established
for PubMed in more details (see Additional file 2).
Data management and selection of studies
Data will be imported using EndNote software (version
X7.2.1, New York, NY, Thomson Reuters, 1988–2014),
where duplicates will be removed. Unique references will
then be exported in Excel software (Excel software 2016,
Microsoft office 2016). An additional file is provided to
describe the procedure of exportation from EndNote to
Excel (see Additional file 3). Two review authors will in-
dependently screen each study by title, abstract, and full
text if necessary for inclusion in the review using the in-
clusion criteria described above. Disagreements will be
resolved by consensus between reviewers or with the in-
volvement of a third reviewer. Studies not written in
French or English will be translated when full text re-
view will be needed, either by review collaborators or
the linguistic department of Laval University.
Data collection process
Data extraction will be performed using an abstraction
form created in Excel (Excel software 2016, Microsoft
office 2016). A preliminary version of that form will be
pilot-tested and customized by two reviewers using five
publications, and the standardized form will be used for
full abstraction. In case of discrepancy, consensus will be
reached with the involvement of a third reviewer.
Incomplete data
We plan to contact the investigators in case of missing
information or if explanation about an important vari-
able is needed. If information on a secondary outcome
variable cannot be obtained, the study will not be in-
cluded in analyses of that outcome. If an included study
reports incomplete information (e.g., means available
but no standard deviations), we will attempt to recalcu-
late values using available data on RevMan software or
with statistical approach proposed by Hozo et al. [21].
Data items
We will extract information on the study (name of the
first author and co-authors, study design, publication
year, publication journal, language of publication, and
source of funding), characteristics of the study popula-
tion (sample size, age, sex, stage of CKD, comorbidities,
duration of illness, past history of fracture, type of drugs
used, treatment center (hemodialysis center, kidney
transplant unit, nephrology department, home dialysis
center), intervention (HD, PD, KT, duration of dialysis,
duration of dialysis before KT, time spent on KT waiting
list), type of comparator (HD, PD, KT, general popula-
tion, non-dialyzed CKD), and outcomes (number of frac-
tures, diagnosis method for fracture, risk of fracture, the
risk of cardiovascular and overall mortality post-fracture,
length of hospitalization post-fracture, number of hospi-
talizations and complications post-fracture, fracture sites
and types).
Assessment of risk of bias in included studies
Methodological quality (internal validity) of RCTs will be
assessed using the Cochrane Collaboration Risk of Bias
Tool [22]. Risk of bias in observational studies will be
assessed with ROBINS-I tool [23] adapted to our review
by the steering committee (comprising two clinicians, an
epidemiologist, a biostatistician, and a review specialist).
This tool consists of six domains (bias due to confound-
ing, bias in selection of participants into study, bias in
classification of interventions, bias due to missing data,
bias in measurement of outcomes, bias in selection of
the reported results) and the interpretation of domain-
level and overall risk of bias judgements. Each separate
domain is rated as “low”, “moderate”, “serious”, “critical”,
or “no information”. The overall assessment is based on
the responses to individual domains.
Summary measures
We will report crude and adjusted risk (prevalence, inci-
dence, rate incidence) of fracture and cardiovascular
mortality post fracture according to intervention and
comparators. For risk of fracture, we considered adjust-
ment for age, sex, and antecedent of fracture (if applic-
able) to represent optimal control for confounders and
any reported adjustment to represent minimal control
for confounders. Continuous variables such as age, mean
duration of CKD, duration of follow-up will be reported
using means and standard deviations.
Data synthesis
The study data will be summarized and analyzed with
Review Manager Software (Revman, Computer program,
Version 5.3 Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2014). Data from similar
studies (using similar measures of frequencies and com-
paring the same outcome in the same groups) will be
combined in meta-analysis if at least three studies are
available by outcome of interest. However, we expect
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that studies will use different measure of frequencies for
the outcomes according to the study design. We also ex-
pect that the duration of follow-up will be different be-
tween studies. Consequently, cumulative incidence or
odds (for risk <0.10) will be converted to incidence rates
using the statistical approach recommended by Rothman
[24] and pooled together. This approach will account for
differences in follow-up duration between studies. Stud-
ies reporting the prevalence of fracture will be pooled
separately. For continuous data, we will use inverse vari-
ance method with random effect models to pool the
standardized mean difference if studies used different
scales for the assessment of the same outcome or mean
difference if studies used the same scale. For dichotom-
ous variables, the data from individual studies will be
combined using Mantel-Haenszel method with random
effects models to pool relative risks). Pooled effect sizes
and their 95% confidence limits will be reported. If
quantitative synthesis is not appropriate, studies will be
described individually according to intervention, com-
parator, and outcomes reported in summary tables.
Measures of treatment effect
For dichotomous variables, the treatment effect will be
calculated using a Mantel-Haenszel random effects
model to estimate pooled relative risks. For continuous
data, we will calculate the treatment effect using random
effects of inverse variance to estimate the standardized
mean difference where studies used different scales for
the assessment of the same outcome and mean differ-
ence where studies used the same method to measure
the outcome. All estimates will be presented with 95%
confidence intervals.
Unit of analysis issues
The overall risk of fracture, risk for specific sites of frac-
ture, cardiovascular and all-cause mortality post-
fracture, and incidence of hospitalization post-fracture
will be analyzed as dichotomous variables. Length of
hospital stay post-fracture will be analyzed as continuous
variables.
Additional analysis
Statistical heterogeneity will be assessed with the Q test
and Cochrane’s I2 [25]. Heterogeneity will be interpreted
as low between 0–30%, moderate between 30–60%, con-
siderable >60% [19].
Clinical outcomes will be analyzed in subgroups ac-
cording to the intervention and comparison (HD vs KT,
HD vs PD, PD vs KT), study design, and type or site of
fracture.
Sensitivity analysis
We will carry out sensitivity analyses to explore the in-
fluence of publication type on results. A sensitivity ana-
lysis will also be performed by removing studies that
have high or unclear risk of bias for RCTs studies and by
removing studies with a serious or critical risk of bias
for observational studies in order to evaluate the robust-
ness of results to potential bias assessed with the
ROBINS-I tool.
Meta-regression
In case of a considerable heterogeneity among studies, a
meta-regression will be performed if the number of
studies is sufficient (>10 by covariate) [19]. Covariates of
interest will be duration of dialysis or kidney transplant-
ation, age of participants, percentage of women, type of
treatments used in dialysis, and after kidney transplant-
ation (corticosteroids, bisphosphonate, vitamin D, phos-
phate chelators), comorbidities (diabetes, hypertension,
obesity, smoking status), cause of ESRD, and ethnicity.
These analyses will be performed using PROC MIXED
(SAS 9.4) [26].
Meta-bias
We will attempt to avoid reporting bias by using a sensi-
tive and reproducible search strategy, including as many
keywords and synonyms as possible. We will also assess
the risk of publication bias with funnel plots if at least
10 studies comparing the same groups of treatment are
included as recommended by the Cochrane handbook
[27]. We will also evaluate the risk of selective reporting
of outcomes within studies by searching for previously
published protocols on registration website (www.con-
trolled-trials.com and clinicaltrials.gov).
Quality of evidence
Overall quality of evidence will be assessed using the
Grading of Recommendations, Assessment, Develop-
ment and Evaluations (GRADE) tool as recommended




Bone disease in CKD is a major health issue leading clin-
ically to increased fracture rates and higher societal costs
due to prolonged length of hospitalization and number
of hospitalization post-fractures [12]. This review will
provide new pooled data on the fracture risk between
three high-risk groups of CKD patients that are on renal
replacement therapy. It will allow us to identify the
group most associated with fracture (if there is a differ-
ence) while the results will potentially reinforce the im-
portance of fractures in CKD population.
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Inform future studies
Considering heterogeneity in methodologies used in ob-
servational studies and the risk of bias associated with
these studies, we expect the results to be heterogeneous.
Our results will therefore guide the implementation of
future preventive strategies targeting patients with high
fracture risk in CKD. Moreover, it will enable future re-
search to focus on new therapeutic treatments aiming at
reducing fracture risk in CKD population. Finally, the
provided details about the methodology used in included
studies in this review will help future studies in improv-
ing their methodology quality.
Limitations
Some elements could represent limitations for the
pooled analysis of this systematic review such as (1) the
statistical and methodological heterogeneity between ob-
servational studies, (2) the type of fracture and methods
used for fracture’s diagnosis, and (3) we may obtain un-
adjusted or incompletely adjusted effect estimates. Also,
the expected number of studies at low risk of bias could
be low. The strength of evidence of our results may thus
be limited by these factors. If sufficient data are avail-
able, we will conduct meta-regression analysis, which
will help to, at least partially, control for potential con-
founding bias. Finally, our secondary objective may be
limited by the fact that we are likely to miss an import-
ant number of studies conceived specifically to estimate
the association between the type of renal replacement
therapy and the risk of post-fracture cardiovascular or
overall mortality.
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